IFRX: Advancing a next-gen C5aR1 inhibitor for ANCA vasculitis with phase II trials starting soon
A strategic shift toward ANCA vasculitis is underway, with a new oral C5aR1 inhibitor (INF904) showing improved safety and pharmacokinetics over prior therapies. Multiple clinical programs are advancing, including a phase II study set to begin early next year, and regulatory engagement is ongoing.B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.